Prion diseases are associated with the conversion of the normal cellular prion protein, PrPC, to the abnormal disease-associated protein, PrPSc. This conversion can be mimicked in vitro using PrPSc isolated from the brains of scrapie-infected animals to induce conversion of recombinant PrPC into a proteinase K-resistant isoform, PrPres. Traditionally, the ‘cell-free’ conversion assay has used, as substrate, recombinant PrPC purified from mammalian tissue culture cells or, more recently, from baculovirus-infected insect cells. The cell-free conversion assay has been modified by replacing the tissue culture-derived PrPC with recombinant PrP purified from bacteria. Bacterial expression and chromatographic purification give high yields of recombinant radiolabelled untagged protein, eliminates artefacts that may be due to cellular factors or antibody fragments normally present in labelled PrP preparations and allows accurate and rapid variation of protein sequence using standard molecular biological techniques. In addition, these cell-free conversion assays were carried out under more physiological conditions, giving more relevance to the assay as a model for conversion. To validate its use in this assay, this bacterial recombinant PrP has been shown to have the conversion properties of mammalian PrPC: (i) it converts to a proteinase K-resistant isoform in the presence of PrPSc; (ii) the efficiency of this conversion by PrPSc of different strains and species parallels that found in vivo; and (iii) its cell-free conversion is inhibited by Congo Red analogues in a structure-dependent manner similar to that seen in in vivo and in vitro cell assays.
BossR. P.,
KoopmanJ. P.,
TheuwsJ. l.,
HendersonP. T.1987; The essential role of the intestinal flora in the toxification of orally-administered benzidine-based dyes: internal exposure of rats to benzidine after intestinal azo reduction. Mut Res 181:327 (Abstract
BossersA.,
BeltP. B. G. M.,
RaymondG. J.,
CaugheyB.,
de VriesR.,
SmitsM. A.1997; Scrapie susceptibility-linked polymorphisms modulate the in vitro conversion of sheep prion protein to protease-resistant forms. Proc Natl Acad Sci U S A 94:4931–4936
BossersA.,
de VriesR.,
SmitsM. A.2000; Susceptibility of sheep for scrapie as assessed by in vitro conversion of nine naturally occurring variants of PrP. J Virol 74:1407–1414
CollinsS. J.,
LewisV. L.,
BrazierM.,
HillA. F.,
FletcherA.,
MastersC. L.2002; Quinacrine does not prolong survival in a murine Creutzfeldt–Jakob disease model. Ann Neurol 52:503–506
DebBurmanS. K.,
RaymondG. J.,
CaugheyB.,
LindquistS.1997; Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc Natl Acad Sci U S A 94:13938–13943
DemaimayR.,
HarperJ.,
GordonH.,
WeaverD.,
ChesebroB.,
CaugheyB.1998; Structural aspects of Congo red as an inhibitor of protease-resistant prion protein formation. J Neurochem 71:2534–2541
DemaimayR.,
ChesebroB.,
CaugheyB.2000; Inhibition of formation of protease-resistant prion protein by Trypan Blue, Sirius Red and other Congo Red analogs. Arch Virol 16:277–283
HopeJ.,
MortonL. J. D.,
FarquharC. F.,
MulthaupG.,
BeyreutherK.,
KimberlinR. H.1986; The major polypeptide of scrapie-associated fibrils (SAF) has the same size, charge distribution and N-terminal protein sequence as predicted for the normal brain protein (PrP). EMBO J 5:2591–2597
HoriuchiM.,
CaugheyB.1999; Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 18:3193–3203
HoriuchiM.,
PriolaS. A.,
ChabryJ.,
CaugheyB.2000; Interactions between heterologous forms of prion protein: binding, inhibition of conversion, and species barriers. Proc Natl Acad Sci U S A 97:5836–5841
JarrettJ. T.,
LansburyP. T.Jr1993; Seeding ‘one-dimensional crystallization’ of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?. Cell 73:1055–1058
KociskoD. A.,
PriolaS. A.,
RaymondG. J.,
ChesebroB.,
LansburyP. T.Jr,
CaugheyB.1995; Species-specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc Natl Acad Sci U S A 92:3923–3927
KorthC.,
MayB. C. H.,
CohenF. E.,
PrusinerS. B.2001; Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 98:9836–9841
LochtC.,
ChesebroB.,
RaceR.,
KeithJ. M.1986; Molecular cloning and complete sequence of prion protein cDNA from mouse brain infected with the scrapie agent. Proc Natl Acad Sci U S A 83:6372–6376
MeyerR. K.,
McKinleyM. P.,
BowmanK. A.,
BraunfeldM. B.,
BarryR. A.,
PrusinerS. B.1986; Separation and properties of cellular and scrapie prion proteins. Proc Natl Acad Sci U S A 83:2310–2314
RaymondG. J.,
HopeJ.,
KociskoD. A.12 other authors1997; Molecular assessment of the potential transmissibilities of BSE and scrapie to humans. Nature 388:285–288
RudykH.,
VasiljevicS.,
HennionR. M.,
BirkettC. R.,
HopeJ.,
GilbertI. H.2000; Screening Congo Red and its analogues for their ability to prevent the formation of PrPres in scrapie-infected cells. J Gen Virol 81:1155–1164
SaborioG. P.,
SotoC.,
KascsakR. J.,
LevyE.,
KascsakR.,
HarrisD. A.,
FrangioneB.1999; Cell-lysate conversion of prion protein into its protease-resistant isoform suggests the participation of a cellular chaperone. Biochem Biophys Res Commun 258:470–475
WellsG. A. H.,
ScottA. C.,
JohnsonC. T.,
GunningR. F.,
HancockR. D.,
JeffreyM.,
DawsonM.,
BradleyR.1987; A novel progressive spongiform encephalopathy in cattle. Vet Rec 121:419–420
ZhangF.,
ZhangJ.,
ZhouW.,
ZhangB. Y.,
HungT.,
DongX. P.2002; Expression of PrPC as HIS-fusion form in a baculovirus system and conversion of expressed PrPsen to PrPres in a cell-free system. Virus Res 87:145–153